Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer
ChiCTR2000031558Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and etoposide in ovarian cancer, sponsored by Beijing Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
anlotinibetoposide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000031558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031558.